Table 1.
PD-L1 expression in various malignant cancers.
| Pathology | Positive no./tested no. | Positive rate (%) | PD-L1 TPS | ||
|---|---|---|---|---|---|
| <1% | 1–49% | ≥50% | |||
| Squamous cell carcinoma (Skin) | 18/20 | 90 | 2 | 2 | 16 |
| Nasal adenocarcinoma | 20/20 | 100 | 0 | 2 | 18 |
| Transitional cell carcinoma | 20/20 | 100 | 0 | 0 | 20 |
| Anal sac gland carcinoma | 19/20 | 95 | 1 | 4 | 15 |
| Soft tissue sarcoma | 14/20 | 70 | 6 | 2 | 12 |
| Osteosarcoma | 20/20 | 100 | 0 | 4 | 16 |
| Malignant melanoma (Oral) | 19/20 | 95 | 1 | 1 | 18 |
| Mammary adenocarcinoma | 20/20 | 100 | 0 | 0 | 20 |
| Histiocytic sarcoma | 18/20 | 90 | 2 | 12 | 6 |
| Diffuse large B-cell lymphoma | 17/20 | 85 | 3 | 5 | 12 |
| Gastric adenocarcinoma | 4/5 | 80 | 1 | 1 | 3 |
| Transmissible venereal tumor | 0/4 | 0 | 4 | 0 | 0 |
TPS tumor proportion score